The Journal of Experimental Medicine
PBL InterferonSource
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 3 November 2003. doi:10.1084/jem.20030267
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 398K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schioppa, T.
Right arrow Articles by Sica, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schioppa, T.
Right arrow Articles by Sica, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2003/11/1391 $5.00
The Journal of Experimental Medicine, Volume 198, Number 9, 1391-1402

Regulation of the Chemokine Receptor CXCR4 by Hypoxia

Tiziana Schioppa1, Badarch Uranchimeg5, Alessandra Saccani1, Subhra K. Biswas1, Andrea Doni1, Annamaria Rapisarda5, Sergio Bernasconi1, Simona Saccani3, Manuela Nebuloni4, Luca Vago4, Alberto Mantovani1,2, Giovanni Melillo5 and Antonio Sica1

1 Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
2 Centro di Eccellenza per l'Innovazione Diangnostica e Terapeutica, Institute of Pathology, State University of Milan, 20133 Milan, Italy
3 Institute for Research in Biomedicine, Bellinzona, CH6500 Switzerland
4 Institute of Pathology, Department of Clinical Sciences L. Sacco, University of Milan, 20157 Milan, Italy
5 Development Therapeutic Program, Tumor Hypoxia Laboratory, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, MD 21702

Address correspondence to Antonio Sica, Istituto di Ricerche Farmacologiche Mario Negri, via Eritrea 62, 20157 Milan, Italy. Phone: 39-02-2390-14530; Fax: 39-02-2332-00231; email: sica{at}marionegri.it; or Giovanni Melillo, Development Therapeutic Program, Tumor Hypoxia Laboratory, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, MD 21701. Phone: (301) 846-5050; Fax: (301) 846-6081; email: melillo{at}dtpax2.ncifcrf.gov

Cell adaptation to hypoxia (Hyp) requires activation of transcriptional programs that coordinate expression of genes involved in oxygen delivery (via angiogenesis) and metabolic adaptation (via glycolysis). Here, we describe that oxygen availability is a determinant parameter in the setting of chemotactic responsiveness to stromal-derived factor 1 (CXCL12). Low oxygen concentration induces high expression of the CXCL12 receptor, CXC receptor 4 (CXCR4), in different cell types (monocytes, monocyte-derived macrophages, tumor-associated macrophages, endothelial cells, and cancer cells), which is paralleled by increased chemotactic responsiveness to its specific ligand. CXCR4 induction by Hyp is dependent on both activation of the Hyp-inducible factor 1 {alpha} and transcript stabilization. In a relay multistep navigation process, the Hyp–Hyp-inducible factor 1 {alpha}–CXCR4 pathway may regulate trafficking in and out of hypoxic tissue microenvironments.

Key Words: cell migration • SDF-1/CXCL12 receptor (CXCR4) • low oxygen concentration • hypoxia-inducible factor 1 (HIF-1)


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS